Kavi Vyas Named Akura Medical’s Chief Commercial and Clinical Officer

February 10, 2026—Akura Medical announced that Kavi Vyas has joined the company as its Chief Commercial and Clinical Officer. Vyas brings industry experience from Medtronic, Penumbra, Viz.ai, Theator, Andromeda Surgical, Hatchleaf, and Plannery.

In this role, Vyas will oversee the commercialization strategy for Akura’s Katana thrombectomy system, enrollment efforts for the QUADRA-PE trial, and key opinion leader engagement. QUADRA-PE is a multicenter prospective single-arm study enrolling 118 patients at up to 26 sites in the United States, Austria, and Brazil. Drs. Sanjum Sethi and Ann Gage are serving as Principal Investigators.

“I am joining Akura because of their commitment to innovation with strong clinical impact,” Vyas told Cardiac Interventions Today. “The combination of AI-powered navigation software, an intelligent console, and feature-rich thrombectomy catheters will help so many patients as we see the evidence support expanded for mechanical thrombectomy. With an incredible team in place and expert clinical advisors, our impact will be outsized.”